Domeki Yasushi, Nakajima Masanobu, Takahashi Masakazu, Kikuchi Maiko, Yokoyama Haruka, Ogata Hideo, Okamoto Kentaro, Yamaguchi Satoru, Sasaki Kinro, Tsuchioka Takashi, Kato Hiroyuki
First Department of Surgery, Dokkyo Medical University, Mibu-machi, Tochigi, Japan.
Department of Paediatric Surgery, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
Tumori. 2020 Apr;106(2):109-114. doi: 10.1177/0300891619869518. Epub 2019 Aug 28.
This study aimed to examine the treatment outcomes of patients with brain metastases from esophageal cancer. Brain metastases from esophageal cancer are rare and have a poorer prognosis than brain metastases from lung and breast cancer.
This study included patients who were diagnosed with and treated for esophageal cancer in our department and subsequently developed brain metastases between April 2010 and December 2014. We examined the differences in survival in patients based on receiving chemotherapy.
In total, 8 patients (7 men and 1 woman) with a mean age of 65 years (range 51-73) were included. Seven presented with neurologic symptoms. Two were diagnosed via computed tomography (CT), 5 via magnetic resonance imaging, and 1 via positron emission tomography/CT. They were treated using whole-brain irradiation or with a gamma knife. In 5 patients, chemotherapy was administered after treatment of the brain metastases. The mean survival from the start of treatment was 358 days (range 31-1196).
The relatively successful local control of brain metastases in these patients indicates that long-term survival may be attainable via concomitant chemotherapy.
本研究旨在探讨食管癌脑转移患者的治疗效果。食管癌脑转移较为罕见，其预后比肺癌和乳腺癌脑转移更差。
本研究纳入了2010年4月至2014年12月期间在我科诊断并治疗食管癌，随后发生脑转移的患者。我们根据是否接受化疗检查了患者生存情况的差异。
共纳入8例患者（7例男性和1例女性），平均年龄65岁（范围51 - 73岁）。7例出现神经症状。2例通过计算机断层扫描（CT）诊断，5例通过磁共振成像诊断，1例通过正电子发射断层扫描/CT诊断。他们接受了全脑照射或伽玛刀治疗。5例患者在脑转移治疗后接受了化疗。从治疗开始的平均生存期为358天（范围31 - 1196天）。
这些患者脑转移的局部控制相对成功，表明通过同步化疗可能实现长期生存。
